Home Healthcare Pharmaceuticals Psoriasis Drug Market

Psoriasis Drug Market Size, Share & Trends Analysis Report By Class Type (Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, Vitamin D Analogues, Corticosteroids, Others), By Treatment Type (Biologics, Corticosteroids, Vitamin D Analogs, Others), By Route of Administration (Parenteral, Oral, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacie, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: March 18, 2026 | Author: Debashree B | Format: | Report Code: SR500DR | Pages: 150
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Psoriasis Drug Market, By Class Type 2022-2034 (USD MILLION/ Units)
    1. Tumor Necrosis Factor Inhibitors
    2. Interleukin Inhibitors
    3. Vitamin D Analogues
    4. Corticosteroids
    5. Others
  2. Psoriasis Drug Market, By Treatment Type 2022-2034 (USD MILLION/ Units)
    1. Biologics
    2. Corticosteroids
    3. Vitamin D Analogs
    4. Others
  3. Psoriasis Drug Market, By Route of Administration 2022-2034 (USD MILLION/ Units)
    1. Parenteral
    2. Oral
    3. Topical
  4. Psoriasis Drug Market, By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Retail Pharmacie
    3. Others
  5. Regional Psoriasis Drug Market
    1. North America
      1. North America Psoriasis Drug Market By Class Type 2022-2034 (USD MILLION/ Units)
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
      2. North America Psoriasis Drug Market By Treatment Type 2022-2034 (USD MILLION/ Units)
        1. Biologics
        2. Corticosteroids
        3. Vitamin D Analogs
        4. Others
      3. North America Psoriasis Drug Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral
        2. Oral
        3. Topical
      4. North America Psoriasis Drug Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Retail Pharmacie
        3. Others
      5. U.S.
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
      6. Canada
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
    2. Europe
      1. Europe Psoriasis Drug Market By Class Type 2022-2034 (USD MILLION/ Units)
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
      2. Europe Psoriasis Drug Market By Treatment Type 2022-2034 (USD MILLION/ Units)
        1. Biologics
        2. Corticosteroids
        3. Vitamin D Analogs
        4. Others
      3. Europe Psoriasis Drug Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral
        2. Oral
        3. Topical
      4. Europe Psoriasis Drug Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Retail Pharmacie
        3. Others
      5. U.K.
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
      6. Germany
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
      7. France
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
      8. Spain
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
      9. Italy
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
      10. Russia
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
      11. Nordic
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
      12. Benelux
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
      13. Rest of Europe
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
    3. APAC
      1. APAC Psoriasis Drug Market By Class Type 2022-2034 (USD MILLION/ Units)
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
      2. APAC Psoriasis Drug Market By Treatment Type 2022-2034 (USD MILLION/ Units)
        1. Biologics
        2. Corticosteroids
        3. Vitamin D Analogs
        4. Others
      3. APAC Psoriasis Drug Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral
        2. Oral
        3. Topical
      4. APAC Psoriasis Drug Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Retail Pharmacie
        3. Others
      5. China
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
      6. Korea
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
      7. Japan
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
      8. India
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
      9. Australia
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
      10. Singapore
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
      11. Taiwan
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
      12. South East Asia
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
      13. Rest of Asia-Pacific
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
    4. Middle East and Africa
      1. Middle East and Africa Psoriasis Drug Market By Class Type 2022-2034 (USD MILLION/ Units)
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
      2. Middle East and Africa Psoriasis Drug Market By Treatment Type 2022-2034 (USD MILLION/ Units)
        1. Biologics
        2. Corticosteroids
        3. Vitamin D Analogs
        4. Others
      3. Middle East and Africa Psoriasis Drug Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral
        2. Oral
        3. Topical
      4. Middle East and Africa Psoriasis Drug Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Retail Pharmacie
        3. Others
      5. UAE
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
      6. Turkey
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
      7. Saudi Arabia
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
      8. South Africa
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
      9. Egypt
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
      10. Nigeria
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
      11. Rest of MEA
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
    5. LATAM
      1. LATAM Psoriasis Drug Market By Class Type 2022-2034 (USD MILLION/ Units)
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
      2. LATAM Psoriasis Drug Market By Treatment Type 2022-2034 (USD MILLION/ Units)
        1. Biologics
        2. Corticosteroids
        3. Vitamin D Analogs
        4. Others
      3. LATAM Psoriasis Drug Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Parenteral
        2. Oral
        3. Topical
      4. LATAM Psoriasis Drug Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Retail Pharmacie
        3. Others
      5. Brazil
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
      6. Mexico
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
      7. Argentina
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
      8. Chile
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
      9. Colombia
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
      10. Rest of LATAM
        1. Tumor Necrosis Factor Inhibitors
        2. Interleukin Inhibitors
        3. Vitamin D Analogues
        4. Corticosteroids
        5. Others
        6. Biologics
        7. Corticosteroids
        8. Vitamin D Analogs
        9. Others
        10. Parenteral
        11. Oral
        12. Topical
        13. Hospital Pharmacies
        14. Retail Pharmacie
        15. Others
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.